Whilst developing PET500, our product for men with premature ejaculation, Futura also expanded its DermaSys® delivery technology platform and produced a new and unique delivery system which does not contain any water, DermaSys® AquaFree. DermaSys® AquaFree enables drugs which are water sensitive (hydrolytically unstable or have only limited hydrolytic stability) to be developed into potentially commercially attractive products with the additional benefit of rapid transdermal delivery. The technology can also be used for drugs that interact with alcohols and glycols.
DermaSys® AquaFree incorporates all the benefits of our well-known DermaSys® technology. DermaSys® is a versatile and bespoke delivery technology in that it can be tailored to suit the specific active compound being used and the therapeutic indication. Such targeted delivery offers an optimised profile in terms of dose, onset time and duration of effect as well as an improved safety profile through lower systemic uptake and the reduced risk of side effects.
In 2011, we signed an exclusive worldwide agreement with Ansell Ltd for the distribution rights to our product for premature ejaculation PET500.
To further maximise the value of DermaSys® AquaFree, Futura is receptive to new product opportunities whether these are developed internally or by a third party.
If you are interested to find out more about the DermaSys® AquaFree technology, please contact us on 01483 685670 or email at info@futuramedical.com.